The Patent Finder

Innovative Cellular Therapeutics Holdings, Ltd.

38 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

0
Ending by 2030
Jul 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 4 to 18, 2027 · next Jan 4
  • 1 fee due Feb 28, 2027
    The maintenance fee for Inducible dominant negative PD-1 and uses in adoptive cell therapy (US 11,739,136) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 2 fees due Apr 3 to 17, 2027 · next Apr 3
  • 3 fees due Jun 3 to 5, 2027 · next Jun 3
  • 2 fees due Jul 2 to 9, 2027 · next Jul 2
  • 1 fee due Aug 18, 2027
    The maintenance fee for Modified Cell Expansion and Uses Thereof (US 10,561,686) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
  • 2 fees due Sep 19, 2027
  • 3 fees due Oct 2 to 30, 2027 · next Oct 2
  • 2 fees due Nov 14 to 19, 2027 · next Nov 14

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,493,139Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
In force (reinstated)
 · USPTO record
In force (reinstated)USPTO record
US 9,572,837Reducing immune tolerance induced by PD-L1
In force
 · USPTO record
In forceUSPTO record
US 10,865,382Reducing immune tolerance induced by PD-L1
In force
 · USPTO record
In forceUSPTO record
US 11,364,289Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
In force
 · USPTO record
In forceUSPTO record
US 12,297,267Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
In force
 · USPTO record
In forceUSPTO record
US 11,932,873Reducing immune tolerance induced by PD-L1
In force
 · USPTO record
In forceUSPTO record
US 10,619,136Reducing immune tolerance induced by PD-L1
In force
 · USPTO record
In forceUSPTO record
US 9,932,405Use of Chimeric Antigen Receptor Modified Cells to Treat Cancer
In force
 · High confidence
In forceHigh confidence
US 10,654,934Use of chimeric antigen receptor modified cells to treat cancer
In force
 · USPTO record
In forceUSPTO record
US 10,793,638Use of Chimeric Antigen Receptor Modified Cells to Treat Cancer
In force
 · High confidence
In forceHigh confidence
10 of 38 patents shown.
Pro members see all 38.
Pro members: see all 38 patents
Also on record, not counted in the 38: 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

13 pending · 4 abandoned · 11 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited